Cover Image

Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure

Francesca Alberton,1 Laura Galli,2 Riccardo Lolatto,2 Caterina Candela,1 Nicola Gianotti,2 Matteo Chiurlo,2 Martina Ranzenigo,2 Martina Strano,2 Alessia Uglietti,3 Antonella Castagna1,2 1Infectious Diseases Unit, Vita Salute San Raffaele University, Milan, Italy; 2Infectious Diseases Unit, San Raffa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Alberton F (Author), Galli L (Author), Lolatto R (Author), Candela C (Author), Gianotti N (Author), Chiurlo M (Author), Ranzenigo M (Author), Strano M (Author), Uglietti A (Author), Castagna A (Author)
Format:	Book
Published:	Dove Medical Press, 2024-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
by: Ranzenigo M, et al.
Published: (2022)

Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]
by: Ranzenigo M, et al.
Published: (2022)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
by: Putcharoen O, et al.
Published: (2015)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
by: Spagnuolo V, et al.
Published: (2019)

Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study
by: Antinori A, et al.
Published: (2019)

Association between time spent with residual viremia after achievement of virological suppression and type of first-line antiretroviral regimen
by: A. Lazzarin, et al.
Published: (2017)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
by: Canetti D, et al.
Published: (2023)

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
by: Squillace N, et al.
Published: (2018)

Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms
by: M. Satya Venkata Sakuntala, et al.
Published: (2021)

Pharmacokinetic interaction between single and multiple doses of darunavir, in combination with cobicistat or ritonavir, and single-dose dabigatran etexilate in healthy adults
by: Sandy Van Hemelryck, et al.
Published: (2024)

A novel simultaneous high performance liquid chromatography-PDA method for the determination of Tenofovir AF, Darunavir, Emtricitabine and Cobicistat in bulk and its application to marketed formulation
by: Challamalla Pavani, et al.
Published: (2022)

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
by: Michael Neely, et al.
Published: (2009)

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study
by: Antinori A, et al.
Published: (2016)

Evaluation of urinary excretion of dolutegravir or emtricitabine/tenofovir/elvitegravir/cobicistat antiretroviral-based regimens using plasma and urine trough concentration
by: Jérémy Lourenco, et al.
Published: (2018)

Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load
by: Phionah Kibalama Ssemambo, et al.
Published: (2021)

Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects
by: Giacomelli A, et al.
Published: (2019)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
by: Pablo Ferrer, et al.
Published: (2020)

Appropriate clinical use of darunavir 800 mg
by: Michelle A. Moorhouse, et al.
Published: (2018)

Combating HIV resistance – focus on darunavir
by: Cécile L Tremblay
Published: (2008)

Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
by: Dobroszycki J, et al.
Published: (2011)

Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens
by: Maha M Elsabaawy, et al.
Published: (2019)

Servicio de dispensación: interacción entre darunavir y quetiapina
by: Damià Barris Blundell, et al.
Published: (2022)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017)

Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
by: Vivek P. Chavda, et al.
Published: (2021)

Molecular Virology
Published: (2012)

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and HBV co-infection
by: Y.-S. Huang, et al.
Published: (2019)

Desenvolvimento de métodos analíticos qualitativos para a análise de darunavir comprimidos
by: Ana Carolina Kogawa, et al.
Published: (2013)

Desenvolvimento de métodos analíticos qualitativos para a análise de darunavir comprimidos
by: Ana Carolina Kogawa, et al.
Published: (2013)

Darunavir Nanoformulation Suppresses HIV Pathogenesis in Macrophages and Improves Drug Delivery to the Brain in Mice
by: Lina Zhou, et al.
Published: (2024)

Depression: an individual-level early warning indicator of virologic failure in HIV patients in South Africa
by: J.A. Edwards, et al.
Published: (2024)

Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study)
by: J. Van Wyk, et al.
Published: (2020)

Is increasing the dose of Entecavir effective in partial virological responders?
by: Erturk A, et al.
Published: (2014)

Lived experiences of students with virological failure on antiretrovirals at a university in Limpopo
by: Mahlodi P. Maphakela, et al.
Published: (2023)

Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study
by: Olivier Ségéral, et al.
Published: (2018)

Research priority-setting for human, plant, and animal virology: an online experience for the Virology Institute of the Philippines
by: Reneepearl Kim Sales, et al.
Published: (2021)

The metagenomic approach and causality in virology
by: Silvana Beres Castrignano, et al.
Published: (2015)

COVID-19: Epidemiology and virology
by: Antariksh Deep, et al.
Published: (2020)

Direct injection HILICâMS/MS analysis of darunavir in rat plasma applying supported liquid extraction
by: Bokka Ramesh, et al.
Published: (2015)

Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting
by: Colombo GL, et al.
Published: (2013)

Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trialResearch in context
by: Fujie Zhang, et al.
Published: (2024)